Calico’s plans to tackle aging are finally taking shape thanks to an agreement with a Texas-based research program. The Google-backed biotechnology company announced it will license and develop potential drugs for neurodegenerative disorders caused by the aging and death of nerve cells after a study showed that P7C3 compounds activate a cellular enzyme involved in energy metabolism that is crucial to the functioning and survival of cells.

READ FULL ARTICLE Curated publisher From San Francisco Chronicle